GLB-001

· Hangzhou GluBio Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for GLB-001, covering 2025-08-19 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes [Phase 1]

See pricing